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appear amenable to education and a more active role in performing tobacco cessation 
interventions in their ofﬁces.
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OBJECTIVES: This study aims at evaluating the attempts to stop smoking and the            
factors related to these attempts in a cohort of smokers followed during 2 years. 
METHODS: A sample of 6032 individuals aged 15 years or more, representative of            
the French population, received a self-administered questionnaire in November 2006. 
Eight hundred and nine smokers were identiﬁed and contacted again in June 2007, 
November 2007, June 2008 and November 2008. A statistical analysis was performed 
on smokers who were reached and interviewed in all phases. RESULTS: In total, 277   
smokers (34%) responded to all interviews. Among them, 10%, 12%, 15%, and 18% 
were quitters in June 2007, November 2007, June 2008, and November 2008, respec-
tively. Seven percent of smokers were consistently quitters at all follow-up interviews. 
Thirty four percent of smokers quitted smoking at least once more than one month 
between two interviews. Smokers who attempted to quit smoking during the follow 
up period (43%) were less dependent to tobacco (p  0.01) and lighter smokers 
(p  0.01). The probability to stop smoking longer than one month decreased in more            
dependant smokers: Odds Ratio  0.77 (CI 95%: 0.67–0.89) and increased in smokers 
with fear of cardiovascular diseases and cancers: Odds Ratio  2.38 (CI 95%: 1.03–
5.50), and medical conditions such as High Blood Pressure, Dyslipidemia, Asthma 
and Diabetes: Odds Ratio  2.42 (CI 95%: 1.10–4.57). Among 42% of smokers who 
declared having intention to stop smoking at the beginning of the study, 50% actually 
did an attempt to quit smoking after a follow up of 2 years. CONCLUSIONS: Half 
of smokers reporting intention to quit did not make an attempt within 2 years. Quit-
ting smoking more than one month was related to dependence to tobacco and current 
health care conditions while fear of smoking-related diseases motivate smokers to quit        
smoking.
URINARY/KIDNEY DISORDERS – Clinical Outcomes Studies
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OBJECTIVES: Comparative data is routinely preferred by reimbursement decision 
makers. The study objective was to estimate the dose relativity of two non-calcium 
based phosphate binders, lanthanum carbonate (LC) and sevelamer hydrochloride 
(SH) in the treatment of end-stage renal disease (ESRD). METHODS: An indirect 
comparison based on a systematic literature review and Bayesian mixed treatment 
meta-analysis methodology was used to determine the equipotent doses of LC and 
SH. The methodology met Australian Pharmaceutical Beneﬁts Advisory Committee 
standards, a rigorous Health Technology Assessment Agency. The outcome measure 
of interest in ERSD was the mean daily dose required to control serum phosphate at 
target levels. The data were analyzed using WinBUGS software. Posterior results were 
estimated using 25,000 samples after a burn-in of 25,000 iterations and thinning the 
MCMC chain every 25 iterations to account for autocorrelation. Goodness-of-ﬁt was 
also assessed. RESULTS: The literature review identiﬁed nine trials and three treat-
ments comparing LC to calcium (6), SH to calcium (2) and SH to LC (1). An uncon-
strained baseline model using a gamma likelihood for the sample mean doses (and 
sample variances) required to achieve a speciﬁc phosphate reduction and control was 
ﬁtted. An a priori assumption was that the population standard deviations between 
treatments were different. The analysis showed that the dose required to achieve 
phosphate reduction and control was 2.33 (95% Crl: 1.75, 3.01) times greater with 
SH versus LC. The dose relatively is consistent with the ratio calculated using the 
World Health Organization’s deﬁned daily dose for LC and SH. CONCLUSIONS: 
This study illustrates how a mixed-treatment comparison can be used to aid in drug 
therapy decision making when direct head-to-head data is limited. Using this approach, 
the dose relativity ratio of the mean daily dose of sevelamer to the mean daily dose 
of lanthanum carbonate was determined as 2.33.
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OBJECTIVES: In Germany, 66,508 patients were on haemodialysis because of chronic          
renal insufﬁciency in 2006. Hyperphosphataemia is the strongest independent risk 
factor for mortality in renal patients. Because a reduction in the ingested phosphate 
intake and hemodialysis are not able to reduce serum phosphate concentrations to 
recommended values, phosphate binders (P-binders) are used to bind ingested phos-
phate in the digestive tract. Besides the traditional therapies calcium- and aluminium 
salts, sevelamer and lanthanum are recent developments on the market. The purpose 
of the present Health Technology Assessment (HTA) was to compare the effectiveness, 
safety and economic efﬁciency of different P-binders in chronic renal insufﬁcient 
patients. METHODS: The systematic literature search yielded 1251 abstracts. Follow-       
ing a two-part selection process with predeﬁned criteria 18 publications were included 
into the assessment. RESULTS: All P-binders effectively controlled serum phosphate,      
calcium and intact parathyroid hormone concentrations. The number of hypercal-
cemic episodes were higher when using calcium-containing P-binders compared to 
sevelamer and lanthanum. Regarding mortality rate, cardiovascular artery calciﬁcation 
and bone metabolism no deﬁnite conclusions could be drawn. Economic studies 
showed higher costs for sevelamer and lanthanum compared to calcium-containing 
P-binders. CONCLUSIONS: The validity of the present HTA is limited due to the           
limited number of available publications, the low sample size of treated patients and 
the fact that the majority of studies were funded by industry and are based on the 
same patient collectives. From a medical point of view, sevelamer showed superiority 
over calcium-containing P-binders at least for special indications.
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OBJECTIVES: To forecast Spanish Renal Replacement Therapy (RRT) trends from 
registry data. METHODS: In Spain, RRT ﬁgures are published yearly by the Spanish 
Nephrology Society (Spanish acronym, SEN) registry. States described include hemo-
dialysis (HD), peritoneal dialysis (PD), and transplant (TX). Both incidence and preva-
lence ﬁgures are provided. The SEN registry gathers data from several regional 
registries. However, an unbalanced panel is faced, as some relevant registries enter or 
exit the analysis from year to year. Drop-outs make SEN ﬁgures highly volatile and 
impractical for epidemiologic or economic studies. Firstly, original data from the SEN 
registry were collected and weighted in order to account for the whole Spanish popula-
tion. Secondly, either linear or quadratic trends were ﬁtted by non-parametric Quantile 
Regression (QR) with bootstrapped standard errors. QR is suitable in the case of tailed 
distributed dependent variables and in the presence of outliers, since it predicts the 
conditional median of the response, instead of its conditional mean (Ordinary Least 
Squares approach). Finally, forecasted RRT ﬁgures were provided and compared to 
the registered data. RESULTS: Weighted Spanish RRT registry data presented strongly 
signiﬁcant trends in the period 1996/2007, as shown by graphical analyses, trend 
coefﬁcients signiﬁcance (p  0.05), and goodness-of-ﬁt of QRs. Positive trends were 
found in HD (R2  0.718), PD (R2  0.538), and TX (R2  0.692) prevalences; and 
in HD (R2  0.719, quadratic), PD (R2  0.526), and TX (R2  0.535) incidences. 
Overall, the predictive performance of the regression models considered was good. 
CONCLUSIONS: SEN registry weighted RRT data display strongly signiﬁcant trends, 
during the period of study, as shown by both graphic analyses and QRs results. Fore-
casted RRT ﬁgures are very useful in epidemiologic or economic studies, overcoming 
the problems, namely the high volatility, observed in published registry data.
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OBJECTIVES: To evaluate the impact on costs of treating complications derived from 
chronic kidney disease (CKD) in patients undergoing hemodialysis in the public health 
care system in Brazil. METHODS: Owing to the lack of local databases, a survey with 
experts was conducted to collect data about the main causes of hospital admissions 
which resulted from complications during the dialysis period of CKD patients. A group 
of 600 patients from reference centers in Brazil was studied. Later, the experts 
answered to a questionnaire about the procedures needed to manage complications. 
Then, a micro-costing was performed, only direct costs were considered: length of 
staying, medical procedures, physician fees and drugs. Sources used for costing were: 
SAI/SIH—SUS (the government reimbursement procedures list), Revista Kairos 
(January 2009) (drugs price list) and Guia Farmacêutico Brasíndice (January 2009) 
(materials price list). The time horizon of this analysis was 1 year, thus no discount 
rate was assumed. The perspective assumed was that of the public payer. RESULTS: 
The 3 most frequent causes of hospital admissions and their respective costs in the 
studied centers were: cardiac complications (33.27%; R$2789); infections (31.90%; 
R$3113); and venous access complications (9.20%; R$2183). For an average patient, 
the total costs in 1 year of treatment were estimated to be R$4358. CONCLUSIONS: 
This study suggests that for the 600 patients studied group the economic impact for 
the public payer with hospital admissions caused by CKD complications is signiﬁcant 
being as high as R$ 2,615,331 in one year.
